in 2021, synbio was priced like software, but scaled like industry. AI makes that narrative more credible today. biological big data + protein models, such as ESM-2 by Meta and AlphaFold by Google Deep Mind, make selection far less blind before capital hits the lab.

"could probably be glorified a bit." is a very handy prompt.

31 years old and still talking about "i cant hang out I have homework"

finance is one of those fields where AI agents are actually useful for both retail and institutions. they can operate independently under predefined rules, which comes in handy for all of us - including institutions seeking DeFi exposure with reliability & auditability.

NIH, 1950s: anglican religious volunteer culture 🤝 a bunch of long-term volunteers enjoying being used as normal controls for metabolic research.

We’re in a world of accelerated science, where governments push innovation for growth, but ethical reflection and meaningful public engagement are not keeping pace. That should concern us, as it risks limiting research’s potential and weakening trust in science as our best evidence-based path.

AI knows the known. it doesn’t have curiosity and doesn’t come up with new ideas

if our bodies are full of microplastics, are we organic waste or recyclable? (image: jd whitman plastiglomerates)

The vision: Synthetic life isn't a risk - it’s a path to safer, bio-contained, scalable environmental technologies. Plastic pollution won’t be solved by “releasing microbes,” but by responsible engineering and closed-loop systems. #GreenChemistry #CircularEconomy #ScienceForGood

it was the start of the pandemic, and I was doing my master’s, but I couldn’t run any experiments because the labs were closed. my philosophy of science blog would’ve turned five today if it were still alive.

It's been 1 and a half months that I've been attending *How to Grow (Almost) Anything*, a graduate-level @medialab.bsky.social bioengineering and synthetic biology course. www.media.mit.edu/courses/htgaa/

Great HS by NCOB. It draws attention to biomedical developments worth keeping on our radar, not only for experts but for society at large. Among them: enantiomeric organisms, AI-enabled genomics, and emerging tools for human genome synthesis.

Biotechnology keeps pushing me back to a basic epistemic question: when research aims at application, how early and in what way should normative goals shape experimental design at the bench?

Meet Brachycephalus lulai journals.plos.org/plosone/arti...

I discovered this podcast yesterday, this is such a nice episode, it seems really interesting studying cultural differences by posing meaningful socio-philosophical questions like those of bioethics (1/2) open.spotify.com/episode/2WDX...

Last week at Biorefineries Powered by Renewable Energies: great talks on biorefinery approaches for energy, materials, food/feed, and other biomass uses. A recurring theme: no one-size-fits-all solution, but advantages to context-aware systems adapting to local biomass and changing conditions.

can organoids/assembloids actually suffer? could we consider that mature ones might have some kind of simple consciousness? if that’s the case, is it (bio)ethical to use them for biomedical research? maybe okay for testing drugs to treat disease, but not for enhancement? where do we draw the line?

Cross‐sectoral citrus sugarcane biorefinery: polyhydroxyalkanoates production in Brazil - Kanbe - 2024 - Biofuels, Bioproducts and Biorefining - Wiley Online Library scijournals.onlinelibrary.wiley.com/doi/10.1002/...